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Abstract
Background: Transmitted drug resistance (TDR) remains an important concern for the management of HIV infection,
especially in countries that have recently scaled-up antiretroviral treatment (ART) access.
Methodology/Principal Findings: We designed a study to assess HIV diversity and transmitted drug resistance (TDR)
prevalence and trends in Mexico. 1655 ART-naı ¨ve patients from 12 Mexican states were enrolled from 2005 to 2010. TDR was
assessed from plasma HIV pol sequences using Stanford scores and the WHO TDR surveillance mutation list. TDR prevalence
fluctuations over back-projected dates of infection were tested. HIV subtype B was highly prevalent in Mexico (99.9%). TDR
prevalence (Stanford score.15) in the country for the study period was 7.4% (95% CI, 6.2:8.8) and 6.8% (95% CI, 5.7:8.2)
based on the WHO TDR surveillance mutation list. NRTI TDR was the highest (4.2%), followed by NNRTI (2.5%) and PI (1.7%)
TDR. Increasing trends for NNRTI (p=0.0456) and PI (p=0.0061) major TDR mutations were observed at the national level.
Clustering of viruses containing minor TDR mutations was observed with some apparent transmission pairs and
geographical effects.
Conclusions: TDR prevalence in Mexico remains at the intermediate level and is slightly lower than that observed in
industrialized countries. Whether regional variations in TDR trends are associated with differences in antiretroviral drug
usage/ART efficacy or with local features of viral evolution remains to be further addressed.
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Introduction
Antiretroviral therapy (ART) has radically decreased HIV-
associated morbidity and mortality in countries where broad
access to antiretroviral (ARV) drugs has been achieved. However,
a wider availability of ART has led to increasing transmission of
HIV variants with reduced susceptibility to ARV drugs
[1,2,3,4,5,6,7,8,9]. Transmitted drug resistance (TDR) can reduce
the efficacy of first-line ARV therapy, as complete suppression of
HIV may be compromised [10]. The presence of resistance
mutations in isolates from ARV-drug-naı ¨ve patients remains an
important concern for the management of HIV infection,
especially in the setting of resource-limited countries that have
recently scaled-up ART access. Nevertheless, most patients in this
setting are starting ART on potent regimens, possibly delaying
transmission of drug-resistant HIV strains as compared with high-
income countries, where ART scale-up began with suboptimal
and lower-potency regimes [11]. This hypothesis is supported by
the observation of stabilizing or decreasing tendencies in TDR in
some developed countries during the last few years, which could be
reflecting the more recent broad use of high-potency ART regimes
[1,12,13,14]. Ongoing TDR surveillance programs using compa-
rable drug resistance definitions are necessary to guide worldwide
efforts to improve treatment outcomes by supplying information to
support education and prevention programs and promote the
rational use of ARV drugs by clinicians and policy makers
[11,15,16,17].
Efforts to provide broad access to ART in Mexico started in
2001 with a universal access program, but it was until 2004 that
coverage for persons without insurance was initiated [18].
Currently, all individuals who approach the Mexican Health
System have access to ART either through the traditional social
insurance program or the popular insurance system, introduced
widely in the population by 2006 [19]. According to data from the
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and UNAIDS, by the end of 2009, 220,000 adults were estimated
to live with HIV in Mexico from which 27% were receiving ART,
14% were under medical follow-up without ART and 59% may
have been unaware of their HIV infection status or were not under
medical follow-up in any public institution [18]. Considering this
scenario, the extent to which TDR has spread in Mexico after
nearly five years of broad access to ART remains an important
issue to be assessed.
The remarkable genetic diversity of HIV has important
implications for multiple aspects of the pandemic such as
diagnostic and follow-up laboratory tests, candidate vaccine
design, susceptibility to ART, transmission capability, virulence
and disease progression [20]. Similarly to other parts of the North
American epidemic, it is estimated that subtype B virus is highly
predominant in Mexico [21,22,23,24]. However, characterization
of HIV molecular epidemiology in the country is incomplete, with
the majority of existing studies being limited to small cohorts of
infected individuals, or focusing on specific geographic areas and
high-risk groups [24,25,26]. Recent studies have shown increasing
trends in HIV diversity in the USA with nearly 4% of non-B
viruses already circulating in the country [7,27]. In Mexico, an
increase in the circulation of non-B subtypes cannot be discarded
either [24].
We established collaborations with several health centers and
HIV clinics in 12 Mexican states, managed mainly by the Mexican
Ministry of Health, to conduct the first large, prospective study to
assess HIV TDR prevalence and trends at the national level. A
cohort of 1655 ART-naı ¨ve patients was formed from 2005 to
2010. Plasma HIV RNA pol sequences were obtained and TDR
was assessed. We observed intermediate TDR levels at the
national level and important regional differences in TDR trends
during the study period, suggesting several scenarios in the
Mexican HIV epidemic and its management in the country.
Materials and Methods
Ethics Statement
Written informed consent was obtained for every participant
before blood sample donation. The study was revised and
approved by the Ethics Committee of the National Institute of
Respiratory Diseases and was conducted according to the
principles of the Declaration of Helsinki.
Patients
We established a national collaborative network between HIV
clinics, state laboratories, regional hospitals and the National
Institute of Respiratory Diseases (INER, a national third-level
referral centre and one of the National Institutes of Health) to
prospectively assess HIV molecular epidemiology and TDR
prevalence and trends in Mexico. Twelve Mexican states that
together account for more than 80% of all the officially registered
HIV infections in Mexico [28] participated in this study (Figure 1).
Newly diagnosed, ART-naı ¨ve HIV patients and individuals
previously diagnosed that had not started ART were enrolled
from 2005 to 2010. After giving written informed consent, patients
donated a single peripheral blood sample. Demographic data was
collected through direct application of a questionnaire before
Figure 1. Geographic distribution of individuals participating in the study. 1655 ART-naı ¨ve individuals from 12 Mexican states were
enrolled in the current study. The percentage of individuals from each state participating in the study is shown in the cake slice to the left. The
proportion of national HIV infections reported for each participating state according to data from the National Centre for HIV/AIDS Prevention and
Control (CENSIDA) [28] is shown in the cake slice to the right.
doi:10.1371/journal.pone.0027812.g001
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the INER in Mexico City within the following 24 hours from
collection. Plasma viral load assays, CD4+ T cell counts and HIV
genotyping and TDR analyses were performed for each
participating individual. Results were sent back to the correspond-
ing health centres for patient clinical follow-up.
HIV sequencing and genotypic drug resistance testing
HIV RNA pol sequences were obtained using ViroSeq HIV-1
Genotyping System (Celera Diagnostics, Alameda, CA), according
to the manufacturer’s specifications, from a fragment of the viral
pol gene including the whole protease (PR) and 334 codons of the
reverse transcriptase (RT). Bulk sequences were obtained with a
3100-Avant Genetic Analyzer (Applied Biosystems, Foster City,
CA). Sequencing PCRs were carried out with 7 different primers
to assure that the whole genomic region was covered with at least
two sequences. Sequences were assembled, aligned to the HXB2
consensus, and manually edited using the ViroSeq v2.7 software
provided by the manufacturer.
Genotypic drug resistance analyses were carried out with the
Stanford HIV Drug Resistance Database algorithm, using the
HIVdb program [29,30]. The presence of resistance was defined
according to Stanford score (SS) ranges as follows: 0–9:
susceptible; 10–14: potential low-level resistance; 15–29: low-level
resistance; 30–59: intermediate resistance; 60 or higher: high-level
resistance. All samples were analyzed at the same time using the
last algorithm update available at the time of writing (Version
6.0.11). Additionally, genotypic drug resistance was defined
according to the presence of drug resistance mutations of the list
for HIV TDR surveillance proposed and periodically updated by
the WHO [31].
TDR surveillance using WHO TDR thresholds
We retrospectively applied the WHO TDR threshold method
for global HIV TDR surveillance to the cohort [11,32]. Patients
under 25 years of age and CD4+ T cell counts over 500 cells/ml
were selected in order to determine TDR thresholds mainly with
individuals infected within a 3-year period before the time of
enrolment. HIV genotypes from the first 47 patients to be
subsequently enrolled that fulfilled the eligibility criteria men-
tioned above, were considered for this sub-analysis as previously
described [11]. The presence of TDR was defined with the WHO
HIV TDR surveillance list [31]. HIV TDR thresholds were
established for twelve-month periods and TDR prevalence was
categorized as low (,5%), moderate ($5%–#15%), or high
(.15%).
Statistical Analyses
TDR prevalence fluctuations were examined over the estimated
time of HIV infection by graphical methods using moving average
with a six-month window. In order to use a date variable closer to
the actual time of HIV infection, a model suggested by Mellors et
al. [33] was used for estimating the delay between HIV infection
and time of diagnosis in the Mexican cohort. Significance was
ascertained with Poisson regression. An ordinal logistic regression
model (lrm from package Design ver 2.3–0) was used to test the
variation of Stanford Scores as a function of CD4+ T cell count
and viral load. All analyses were carried out with R statistical
software version 2.12.0.
HIV subtyping and phylogenetic analyses
HIV subtyping was performed with REGA Subtyping Tool v2.0
[34,35], available on line. Recombination was confirmed using
RIP HIV Recombination Identification Program [36], available
on line. We used PhyML ver 2.4.4 to estimate the maximum
likelihood phylogeny of protease and RT sequences separately,
with 100 replicates for bootstrap analysis, and a GTR+I+gamma
base optimization model. The resulting trees were explored with
the R package ‘‘ape’’, version 2.7–3 [37], to look for possible
transmission clusters and geographical effects.
We selected the most frequent TDR mutations for PI, NRTI
and NNRTI (A71V, G333E and K103R, respectively) to examine
transmission patterns of specific mutations in the trees. In order to
control for the possibility that the branch convergence observed
was due to having the TDR mutation itself, we selected tree tips
(patients) that had the TDR mutation studied and bootstrapping
support in the tree of the other gene; that is, we looked for
bootstrap values for patients with K103R and G333E in the
protease tree, and for A71V in the RT tree, since these changes
were not used to build each of those trees.
Results
TDR levels and HIV diversity in Mexico
We prospectively analyzed for TDR the HIV protease-RT
sequences of 1655 ART-naı ¨ve individuals from 12 Mexican states,
between 2005 and 2010. The samples collected came from
Mexican states that together account for 82.8% of all the officially
reported cases in the country [28]. In general, the proportion of
patients enrolled for each state in the study was similar to the
proportion of the total number of infections officially reported for
that state, although some states were over or under represented in
the cohort (Figure 1).
The Mexican cohort included a high proportion of individuals
in late stages of HIV disease, with a median CD4+ T cell count of
228 cells/ml (Table 1). This characteristic late detection of HIV
infection has been previously recognized in Mexico [18]. Nearly
half of the participating individuals were diagnosed with CD4+ T
cell counts under 200 cells/ml, and 18% under 50 cells/ml. Four
out of five patients enrolled were male and the mean age at
enrolment was 32.5 years (Table 1). No increasing or decreasing
trends were seen in the proportion of females enrolled during the
study period (p=0.11).
An unexpectedly high frequency of clade B viruses was found in
the Mexican cohort, with 99.9% (1653/1655) of the viruses
belonging to this subtype. Only two non-B sequences were found,
belonging to the CRF12-BF and the CRF06-cpx circulating
recombinant forms. The patients presenting these recombinant
viruses referred having high-risk activities for HIV infection in
South America and Europe respectively.
A global TDR prevalence of 7.4% (122/1655, 95% confidence
interval [CI] 6.2:8.8) to any ARV drug was found for the whole
study period using Stanford scores (SS) with a threshold value of
15 (at least low-level ARV drug resistance). This definition of TDR
was comparable to the one based on the WHO TDR surveillance
mutation list [31], which predicted a general TDR prevalence for
any ARV drug of 6.8% (113/1655, 95% CI 5.7:8.2) (Table 2).
Using a Stanford score threshold of 15, the prevalence of TDR
resistance to nucleoside RT inhibitors (NRTIs) was the highest
(69/1655, 4.2%, 95% CI 3.3:5.3), followed by non-nucleoside RT
inhibitors (NNRTIs) (42/1655, 2.5%, 95% CI 1.9:3.4) and
protease inhibitors (PIs) (28/1655, 1.7%, 95% CI 1.1:2.5)
(Table 2). TDR to NNRTIs was lower using the WHO TDR
surveillance mutation list definition compared to the Stanford
algorithm, which takes into account the additive effect of minor
mutations such as K101Q, K103R and V179D for global
resistance levels. High-level ARV drug resistance (SS$60) was
HIV Transmitted Drug Resistance in Mexico
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PIs (14/1655, 0.8%) or NRTIs (6/1655, 0.4%) (Table 2). The
prevalence of TDR to multiple drug classes was low with 0.8%
(13/1655) and 0.1% (2/1655) of patients showing resistance to two
or three drug classes respectively.
It is important to note that a lower SS cut-off provides greater
sensitivity for identifying individuals with true phenotypic
resistance, but lower specificity, capturing more false positives.
However, as stated above, a SS cut-off of 15 best correlates with
the use of the WHO TDR mutation list for defining resistance and
even if phenotypic resistance were not present, the existence of
TDR mutations with low SS could be indicative of selection by
ARV drugs and could be relevant to study TDR transmission.
We retrospectively applied the WHO TDR threshold method
for TDR surveillance in the Mexican cohort. Selecting individuals
under 25 years of age and $500 CD4+ T cells/ml, TDR levels in
Mexico were in the moderate range ($5%–#15%) for 2008 and
2009. This categorization persisted when considering individuals
under 25 years of age and .350 CD4+ T cells/ml in six-month
period analyses for both years.
Among individuals with TDR, high-level resistance (SS$60)
was observed more frequently to nevirapine (26/122, 21.3%),
delavirdine (23/122, 18.9%), efavirenz (20/122, 16.4%), nelfinavir
(15/122, 12.3%), emtricitabine (5/122, 4.1%) and lamivudine (5/
122, 4.1%), while zidovudine (57/122, 46.7%) and stavudine (53/
122, 43.4%) were the ARV drugs most frequently affected by at
least low-level TDR (Figure 2).
Most NRTI TDR cases were associated with the presence of
thymidine analogue mutations (TAMs), with 70.4% (57/81) of the
viruses with any degree of NRTI resistance (SS$10) expressing at
least one TAM. From all the NRTI TDR cases 1.2% (1/81),
11.1% (9/81), and 8.6% (7/81) showed the combination of 4, 3,
and 2 TAMs respectively, and 49.4% (40/81) presented a single
TAM. Among individuals with more than 1 TAM, 70.6% (12/17)
showed a type 1 mutation pathway (M41L, L210W, T215
revertants), while the rest showed a type 2 mutation pathway
(D67NG, K70R, T215 revertants, K219RQEN). Interestingly,
44.4% (36/81) of the NRTI resistance cases showed the presence
of RT T215 revertants, suggesting ARV drug-dependent selection
and transmission of drug resistance mutations. The M184VI
mutation was detected in 5 individuals (0.3% of the whole cohort,
7.2% of individuals with NRTI TDR) while mutations of the
Q151M complex were not observed (Table 3).
The NNRTI resistance mutation K103NS was present in 1.1%
(18/1655) of the cohort and explained about 70% of high-level
NNRTI resistance cases (Table 3). Low-level resistance cases were
generally explained by the combination of minor mutations such
as K101QE, K103R and V179D. Remarkably, the K103R minor
mutation was found in 7.2% (119/1655) of all the individuals
included in the study and in 11.9% (5/42) of individuals with
NNRTI TDR (Table 2). This is a significantly higher occurrence
than the 2% expected in ART naı ¨ve, clade B-infected cohorts and
the 3.5% expected in NNRTI-experienced cohorts [38].
The presence of L90M explained all the cases of high-level PI
TDR (14/14), while M46IL explained most of the intermediate-
level PI TDR cases (12/14). Characteristically, 64.3% (18/28) of
PI TDR cases showed the presence of more than one PI
resistance-associated mutation (range 2 to 6). Interestingly, the
polymorphic A71T/V mutation in protease was found in nearly
one fourth of the individuals enrolled in the study (406/1655),
compared with the 2–3% expected in PI-untreated populations
[38] and in 50% (14/28) of individuals with PI TDR. Similarly,
the V10IV mutation was observed in 12.3% (204/1655) of all the
individuals in the cohort (with an expected prevalence of 5–10% in
untreated persons [38]) and 32.1% (9/28) of individuals with PI
TDR (Table 3).
Table 1. Demographic and clinical characteristics of individuals with and without TDR in the Mexican cohort.
Total Susceptible
a TDR (SS$10) TDR (SS$15) TDR (SS$30) TDR (SS$60)
n 1655 1426 228 122 78 41
Mean Age (years, [IQR]) 32.5 [25:38] 32.6 [25:38] 32.1 [25:38] 31.9 [25:38] 30.4 [24.5:35] 29.5 [23:35]
Proportion of Females [n (%)] 337 (20.4) 294 (20.6) 43 (18.8) 18 (14.8) 8 (10.3) 5 (12.2)
Median Viral Load, (RNA copies/mL,
[IQR])
74,474
[21,295:251,387]
74,270
[21,607:244,000]
79,510
[20,105:303,703]
57,189
[18,495:293,059]
39,729
[10,828:234,000]
51,538
[17,417:369,507]
Median CD4+ T cell count, (cells/mL,
[IQR])
227.8 [82.4:417.6] 227.9 [83:422] 227.6 [72.3:390] 249 [71.5:439] 253 [83.2:482.4] 253 [103:456.8]
aIndividuals with Stanford Scores lower than 10. TDR – Transmitted Drug Resistance; SS – Stanford Score; IQR – Interquartile Range.
doi:10.1371/journal.pone.0027812.t001
Table 2. TDR prevalence in a cohort of 1655 ART-naı ¨ve Mexican individuals from 12 states.
Drug Class TDR Level [n (%, 95% confidence interval)]
a
SS$10 SS$15 SS$30 SS$60 WHO
Any ARV Drug 228 (13.8, 12.2:15.6) 122 (7.4, 6.2:8.8) 78 (4.7, 3.8:5.9) 41 (2.5, 1.8:3.4) 113 (6.8, 5.7:8.2)
NRTI 80 (4.8, 3.9:6.0) 69 (4.2, 3.3:5.3) 26 (1.6, 1.0:2.3) 6 (0.4, 0.1:0.8) 69 (4.2, 3.3:5.3)
PI 51 (3.1, 2.3:4.1) 28 (1.7, 1.1:2.5) 28 (1.7, 1.1:2.5) 14 (0.8, 0.5:1.5) 29 (1.8, 1.2:2.5)
NNRTI 118 (7.1, 6.0:8.5) 42 (2.5, 1.9:3.4) 32 (1.9, 1.3:2.8) 26 (1.6, 1.0:2.3) 31 (1.9, 1.3:2.7)
aData shown is number, percentage and 95% confidence interval. SS – Stanford Score; ARV – Antiretroviral; NRTI – Nucleoside Reverse Transcriptase Inhibitors; PI –
Protease Inhibitors; NNRTI – Non-Nucleoside Reverse Transcriptase Inhibitors.
doi:10.1371/journal.pone.0027812.t002
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characteristics between subjects with and without TDR (Table 1).
Nevertheless, a logistic regression model showed that individuals
with any TDR mutation had a tendency to present higher viral
loads (p=0.0374) (Table S1). Although stratification in SS
apparently reflects lower viral loads associated with higher scores
(Table 1), the number of subjects in each strata also decreases,
making the patients with SS between 10 and 15 represent almost
half of all the TDR cases, and therefore contributing more
statistical weight to the model. Interquartile ranges in Table 1 also
convey that the upper boundary of viral load is mostly higher in
individuals with TDR than in individuals with susceptible viruses.
No differences were found in general TDR levels between the
Mexican states included in the study. However, different clinical
and demographic characteristics such as median plasma viral load,
median CD4+ T cell count, mean age and percentage of females
were observed in the subjects enrolled in different geographical
regions, suggesting different epidemiological scenarios and clinical
management of the infection in different areas of the country
(Table S2).
TDR trends in Mexico
Since 83.2% of the individuals in our cohort were diagnosed
within 3 months prior to blood sample collection, and given the
generally advanced stage of HIV disease at diagnosis (Table 1),
there was a large gap between infection time and time of diagnosis.
In order to use a date variable closer to actual HIV infection time,
we used the model suggested by Mellors et al. [33] for estimating
the delay between infection and diagnosis. Since the model
assumes a CD4+ T cell count of 800 cells/uL at the time of
infection, we used time of diagnosis for all values .=800 to avoid
estimation of infection dates later than HIV+ diagnosis dates. The
back-projected dates derived from this model showed that patients
in the cohort were infected between April 1991 and February
2010. Half of the patients were probably infected before August
2001 (interquartile range: October 1998 to February 2003).
Using a graphic moving-average method over the estimated
HIV infection dates, a significant increasing trend was observed at
the national level, when considering NNRTI major TDR
mutations alone (p=0.0456), and PI major TDR mutations alone
(p=0.0061) (Figure 3). No significant TDR trends were observed
in regional analyses for NNRTIs or for PIs (Figure S1). Although a
significant decreasing trend at the national level was not apparent
for NRTIs (p=0.0653), a strong decreasing trend in NRTI major
TDR mutation frequency was observed in the Northwest region of
the country, including a large proportion of individuals from the
border city of Tijuana (p=0.0074) (Figure S1).
Additionally, 14 TDR mutations showed trends of higher or
lower prevalence in specific regions (p,0.05), from which 2
remained significant after correction for multiple comparisons
(q,0.2) (Table S3); i.e. K103R with a higher prevalence in the
Northeast and G333E with a higher prevalence in the West.
Phylogenetic analyses
In order to establish the existence of possible TDR transmission
clusters, we estimated maximum likelihood phylogenies for
protease and RT sequences from all the participating individuals
(Figure S2). The resulting trees were explored with R package
‘‘ape’’. We observed scarce support for inner nodes, but several
strongly related sequences in pairs or small clusters towards the
tips of the branches. This suggests a high similarity between the
sequences in the cohort, with no large geographical effects.
Sequences with some minor TDR mutations appeared to form
large clusters (Figure S2). Within these clusters, probable
transmission pairs were detected, with sequences from the same
geographical regions and close genetic distances. However, we also
found well supported nodes that included sequences from distant
geographical regions and large genetic distances, possibly
suggesting a wider circulation of these mutations at a population
level (Figure 4).
Discussion
We present results from the largest national study to date
assessing HIV molecular epidemiology and TDR prevalence and
trends in Mexico. The study included states that together report
more than 80% of all the infection cases in Mexico (Figure 1).
Taking the 7.4% prevalence of TDR in the whole sample as an
effect size, 80% power, and 0.05 significance, we estimated that a
sample size of 1434 subjects was necessary for testing proportions.
Considering that the study cohort was composed of 1655
individuals, a high representativity was achieved. Indeed, the
Mexican Cohort reflected the previously characterized late
detection of HIV infection, the lower prevalence of infection
Figure 2. Antiretroviral drug (ARV) resistance levels to the most common antiretroviral drugs among individuals with transmitted
drug resistance (TDR). The levels of ARV drug resistance in the 122 of 1655 individuals with TDR in the Mexican cohort are shown. Low-level
resistance corresponds to a Stanford Score (SS) between 15 and 29, intermediate-level resistance to a SS between 30 and 59, and high-level resistance
to a SS equal to or over 60.
doi:10.1371/journal.pone.0027812.g002
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higher prevalence of the infection in the 30–44 age group (48% of
the officially reported cases) (Table 1) [28].
Only 0.1% of the circulating viruses were identified as non-B
subtypes. This prevalence is remarkably lower that that observed
in the USA and Canada [7,8], even after considering the
geographic proximity and migratory efflux between these
countries.
TDR prevalence in the country was shown to be at an
intermediate range, according to WHO thresholds, and was
slightly lower than that observed in some industrialized countries
[1,4,6,7,14]. Although broad access to ART has been functional in
Mexico for five years, the fact that nearly 60% of infected persons
may be unaware of their serological status [18] could explain a
slower spread of TDR in the Mexican setting, as less than half of
the individuals who need ART would actually be receiving it [39].
A recent study by Wheeler and others [7] reported higher TDR
levels in the USA compared to those observed in Mexico in the
present study for similar time periods. Different TDR mutation
patterns were also apparent in both countries: For PIs, M46IL
(43% vs 21%; p=0.0112, q=0.1915) and L90M (50% vs 27%;
p=0.0056, q=0.1911) were more prevalent in Mexico; for
NRTIs, T215 revertants were more prevalent in Mexico (52%
vs 36%, p=0.0011, q=0.0171) and T69N was more prevalent in
the USA (1% vs 22%, p=0.0012, q=0.0171). Although
differences exist in the design of both studies, these observations
may reflect real epidemiological differences in TDR trends in the
USA and Mexico. Comparisons in HIV TDR between the two
countries are interesting given their geographical proximity,
characteristic migratory patterns and differences in HIV disease
management and policies. Taken together, these observations
suggest different scenarios for HIV TDR in the two countries and
have implications for HIV/AIDS management in the region as
they might reflect a relatively closed contact network among
migrants that acquire the infection abroad due to increased risk
behaviour [40].
It is noteworthy that the CD4+ T cell counts of the newly
diagnosed individuals were fairly low, with approximately half
below 200 cells/uL (Table 1). Thus, considering that individuals in
the Mexican setting frequently wait until they have symptoms to
receive a positive HIV diagnosis, then individuals in our cohort
could potentially reflect TDR several years earlier when they were
likely to be infected. If TDR is related to calendar time reflecting
scaling up of broad access to ART that started in 2001, then the
TDR prevalence represented by this population might not be
reflecting the current TDR prevalence as the current newly
infected individuals are under-represented in the study population.
In order to assess this issue, we used a previously reported model to
estimate the delay between HIV infection and diagnosis [33]. HIV
infection dates were back projected and TDR trends in time
estimated. National TDR trends were stable when considering all
TDR mutations within the period of 1994 to 2010, comprising the
back-projected dates of infection of the individuals in the cohort.
However, significant increasing trends were apparent for NNRTI
and PI major mutations, as expected and observed in other
countries that have implemented broad-access programs to ARV
therapy [2,6,7,11]. Nevertheless, a stable national trend and a
decreasing trend in the Northwest for NRTI TDR are consistent
with observations in other countries that report reductions in TDR
prevalence, which may be associated with the broad use of high-
potency, first-line ART regimes [1,12,14]. Indeed, only four high-
potency ARV drug combinations account for half of all the
prescribed schemes in Mexico, namely TDF + FTC + EFV
(20.6%), ZDV + 3TC + EFV (14.8%), TDF + FTC + LPV/r
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that the majority of ARV drug combinations prescribed as first-
line ART regimens in Mexico do not contain PIs. Thus, it is
possible that the increasing trend in PI TDR observed in the
present study may be partly associated with increasing use of this
ARV drug family in second-line/salvage ART regimens. Although
regional differences in TDR trends were scarce in the present
study, the existence of multiple scenarios in HIV management and
molecular epidemiology within the country cannot be discarded,
and will need further assessment.
Several questions remain about the origin of TDR in the
Mexican setting. According to data from the National System for
ARV Drug Management, Logistics and Surveillance (SALVAR) at
the National Centre for HIV/AIDS Prevention and Control
(CENSIDA) [41], it is noteworthy that from all individuals under
ART in Mexico, 89% have at least one registered viral load assay
after ART initiation, and only 63% individuals with 6 or more
months under ART have viral loads under 400 copies/ml [39,41].
Stratifying these data by state, a negative correlation was found
between the prevalence of PI TDR and the proportion of persons
with at least one viral load assay registered during ART follow-up
(p=0.0188, r
2=0.4757, data not shown). This suggests an
important role of suboptimal clinical follow-up of individuals
under ART in HIV TDR spread among the population. On the
other hand, several polymorphic ARV drug resistance-associated
mutations showed a high frequency in the Mexican cohort
compared to other ART-naı ¨ve cohorts [7,38], including T215
revertants and K103R in RT; and A71TV, M46IL and L90M in
protease. This could suggest the existence of important founder
effects defining polymorphism spread in circulating HIV in
Mexico in which other selective pressures such as HLA-mediated
immune responses may be involved. Moreover, the fact that some
ARV drug resistance-associated mutations were differentially
expressed in different geographic areas suggests that several
founder effects could be involved in TDR mutation spread in the
country. Interestingly, a phylogenetic analysis of the 1655 Mexican
viral sequences showed a marked clustering of sequences
containing some minor TDR mutations. In particular, distinctive
Figure 3. Transmitted drug resistance (TDR) trends in Mexico at the national level. Approximate dates of infection were estimated using a
model described by Mellors et al [33]. TDR fluctuations were examined over the back-projected dates of infection by graphical methods using moving
average with a six-month window. Significance was assessed with Poisson regression. Trends considering all TDR mutations and only major TDR
mutations are shown.
doi:10.1371/journal.pone.0027812.g003
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PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27812Figure 4. Sub-trees for specific protease and RT TDR mutations. Sub-trees were formed by selecting the patients that had a specific TDR
mutation in one of the two genes, from the complete tree based on the other gene (see text for details). Zoom-ins on representative branches are
shown on the right, expanding the information on the patients: State | Gender | date of sample collection | probable date of infection. Several
branches (e.g. c and e) showed probable transmission pairs, while others formed small clusters with pairs within them (a and d). b and d show cases
of widely circulating viruses with TDR mutations. Red lines show branches with boostrap values .90% for A71V and G333E, and blue lines for K103R.
Lighter shades show bootstrap support .80%.
doi:10.1371/journal.pone.0027812.g004
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the RT G333E and K103R mutations were observed, when
considering all the sequences together (Figure 4, Figure S2).
Several possible transmission pairs were identified in these clusters.
Although a geographical effect could be detected within some of
the clusters, the inclusion of sequences from distant geographical
regions and varied genetic distances in others was also apparent,
suggesting a wide circulation of these mutations in Mexico. These
data suggest a possible role of viral evolution in TDR spread in
Mexico. However, the extent to which different ART manage-
ment policies, patient follow-up and physician and patient
education may influence TDR spread remains to be further
assessed.
The current study represents the largest and most comprehen-
sive study to date assessing HIV molecular epidemiology and
TDR prevalence in Mexico. We show that TDR prevalence in
Mexico remains at an intermediate level. Our data strongly
suggests the presence of selection and transmission of TDR
mutations in unique and complex patterns within the country.
Further and continuous TDR surveillance is necessary to gain
more in-depth knowledge on TDR spread and patterns in Mexico,
and to confirm the trends observed in this study. Whether regional
variations in TDR patterns and trends are associated with
differences in ARV drug usage/ART efficacy or with founder
events in viral evolution in different geographic areas within the
country remains to be further addressed.
Supporting Information
Figure S1 Regional transmitted drug resistance (TDR)
trends in Mexico. Approximate dates of infection were
estimated using a model described by Mellors et al [33]. TDR
fluctuations were examined over the estimated dates of infection
by graphical methods using moving average with a six-month
window for each geographic region. Significance was assessed with
Poisson regression. Center – Mexico City, Morelos, Tlaxcala,
Puebla, State of Mexico; East – Veracruz, Quintana Roo; NE –
Nuevo Leo ´n, Guanajuato, Queretaro; NW – Sinaloa, Sonora,
Baja California; South – Oaxaca, Guerrero, Chiapas; West –
Jalisco, Michoacan.
(TIFF)
Figure S2 Phylogenetic Maximum Likelihood (ML) tree
of the protease (A) and reverse transcriptase (B)
nucleotide sequences of 1655 Mexican individuals. The
ML tree was estimated using PhyML ver 2.4.4, with 100 replicates
for bootstrap analysis, and a GTR+I+gamma base optimization
model. Bootstrap support from 100 replicates is shown for values
.50%.
(TIFF)
Table S1 Ordinal logistic regression model of the effect
of CD4+ T cell count and plasma viral load on the
Stanford scores of all patients
a.
(DOC)
Table S2 TDR prevalence and demographic/clinical
characteristics of a cohort of the Mexican cohort by
state.
(DOC)
Table S3 ARV drug resistance mutations expressed
differentially in viruses from different geographic
regions in Mexico.
(DOC)
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